Heart transplant patients may soon take just one pill a day
NCT ID NCT03373227
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a once-daily version of the anti-rejection drug tacrolimus (Envarsus) works as well as the standard twice-daily version (Prograf) in heart transplant recipients. Fifty adults who had a heart-only transplant were enrolled. The goal was to see if the easier once-daily dosing could improve medication compliance and reduce the risk of organ rejection or graft failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus (Envarsus and Prograf)
What this could lead to
If successful, this could show that a once-daily pill is as effective as twice-daily dosing, making it easier for heart transplant patients to stick to their medication schedule and potentially reduce rejection risks.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to all patients. The study is also open-label, meaning both patients and doctors know which drug is given, which can introduce bias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLIANCE, PATIENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States